Macitentan for the Treatment of Pulmonary Arterial Hypertension

Annals of Pharmacotherapy

Volumn 48, Issue 4, 2014, Pages 538-547

  Hong, Irene S ^a   Coe, Holly V ^a   Catanzaro, Linda M ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

ACT 064992; endothelin receptor antagonist; macitentan; pulmonary arterial hypertension

Indexed keywords

ACT 132577; ALANINE AMINOTRANSFERASE; AMBRISENTAN; ASPARTATE AMINOTRANSFERASE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DRUG METABOLITE; HEMOGLOBIN; KETOCONAZOLE; MACITENTAN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTANOID; RIFAMPICIN; SILDENAFIL; UNCLASSIFIED DRUG; WARFARIN; ENDOTHELIN RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACUTE RESPIRATORY FAILURE; ANEMIA; AREA UNDER THE CURVE; BRONCHITIS; CLINICAL PHARMACOLOGY; COUGHING; DISEASE EXACERBATION; DIZZINESS; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FORMULARY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; EMBASE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOXIA; INFLUENZA; LIVER FAILURE; MEDLINE; MORBIDITY; MORTALITY; NONHUMAN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; RHINOPHARYNGITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC HEPATITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; ENDOTHELIN RECEPTOR ANTAGONISTS; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; PYRIMIDINES; SULFONAMIDES;

EID: 84898680570     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013518900     Document Type: Review

References (53)

1. Centers for Disease Control and Prevention. Pulmonary hypertension factsheet. http://www.cdc.gov. Accessed October 24, 2013.
2. Barst RJ,McGoon MD,Torbicki A, et al.Diagnosis and differential assessment of pulmonary arterial hypertension.J Am Coll Cardiol. 2004;43:S40-S47.
3. Badesch DB,Champion HC,Gomez Sanchez MA, et al.Diagnosis and assessment of pulmonary arterial hypertension.J Am Coll Cardiol. 2009;54:S55-S66.
4. Simonneau G,Robbins IM,Beghetti M, et al.Updated clinical classification of pulmonary hypertension.J Am Coll Cardiol. 2009;54:S43-S54.
5. National Heart Blood, Lung, and Blood Institute. What is pulmonary hypertension?http://www.nhlbi.nih.gov/health/health-topics/topics/pah/. Accessed October 24, 2013.
6. Humbert M,Sitbon O,Simonneau G.Treatment of pulmonary arterial hypertension.N Engl J Med. 2004;351:1425-1436.
7. Archer SL,Weir EK,Wilkins MR.Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.Circulation. 2010;121:2045-2066.
8. McLaughlin VV,Archer SL,Badesch DB, et al.ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.J Am Coll Cardiol. 2009;53:1573-1619.
9. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2013:.
10. Galie N,Hoeper MM,Humbert M, et al.Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).Eur Heart J. 2009;30:2493-2537.
11. Research Triangle Park, NC: United Therapeutics Corp; 2013:.
12. US Food and Drug Administration (FDA). Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed November 20, 2013.
13. CenterWatch. Pulmonary arterial hypertension. http://www.centerwatch.com/clinical-trials/results/new-therapies/nmt-details.aspx?CatID=702. Accessed October 27, 2013.
14. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc; 2013:.
15. Formulary®. Pfizer voluntarily withdraws sitaxsentan from the market worldwide and halts ongoing clinical trials. http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/pfizer-voluntarily-withdraws-sitaxsentan-marke. Accessed October 29, 2013.
16. US Food and Drug Administration (FDA). FDA approves Opsumit® to treat pulmonary arterial hypertension. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm371362.htm. Accessed October 29, 2013.
17. Bolli MH,Boss C,Binkert C, et al.The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.J Med Chem. 2012;55:7849-7861.
18. Iglarz M,Binkert C,Morrison K, et al.Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.J Pharmacol Exp Ther. 2008;327:736-745.
19. Sidharta PN,van Giersbergen PL,Dingemanse J.Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.J Clin Pharmacol. 2013;53:1131-1138.
20. Bruderer S,Hopfgartner G,Seiberling M, et al.Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans.Xenobiotica. 2012;42:901-910.
21. SidhartaPNLindeggerN, Ulc I, Dingemanse J. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment [published online October3, 2013]. J Clin Pharmacol. http://www.ncbi.nlm.nih.gov/pubmed/24122797. Accessed October 23, 2013. doi:10.1002/jcph.193.
22. Bruderer S,Marjason J,Sidharta PN,Dingemanse J.Pharmacokinetics of macitentan in Caucasian and Japanese subjects: the influence of ethnicity and sex.Pharmacology. 2013;91:331-338.
23. PulidoTAdzerikhoIChannickRN. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-818. http://www.nejm.org/doi/suppl/10.1056/NEJMoa1213917/suppl_file/nejmoa1213917_appendix.pdf. Accessed October 23, 2013. doi:10.1056/NEJMoa1213917.
24. Sidharta PN,van Giersbergen PL,Halabi A,Dingemanse J.Macitentan: entry-into-humans study with a new endothelin receptor antagonist.Eur J Clin Pharmacol. 2011;67:977-984.
25. RaghuGMillion-RousseauRMorgantiAPerchenetLBehrJ; MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial [published online May16, 2013]. Eur Respir J. http://www.ncbi.nlm.nih.gov/pubmed/?term=raghu+2013+macitentan. Accessed October 31, 2013. doi:10.1183/09031936.00104612.
26. Pulido T,Adzerikho I,Channick RN, et al.Macitentan and morbidity and mortality in pulmonary arterial hypertension.N Engl J Med. 2013;369:809-818.
27. Raghu G,Collard HR,Anstrom KJ, et al.Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.Am J Respir Crit Care Med. 2012;185:1044-1048.
28. King TE,Behr J,Brown KK, et al.BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2008;177:75-81.
29. King TE,Brown KK,Raghu G, et al.BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med. 2011;184:92-99.
30. Raghu G,Behr J,Brown KK, et al.Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.Ann Intern Med. 2013;158:641-649.
31. ClinicalTrials.gov. Long-term extension study of the SERAPHIN study, to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension (SERAPHIN OL). http://www.clinicaltrials.gov/ct2/show/NCT00667823?term=macitentan&rank=11. Accessed October 27, 2013.
32. ClinicalTrials.gov. SYMPHONY: a study of macitentan in pulmonary arterial hypertension to validate the PAH-SYMPACT. http://www.clinicaltrials.gov/ct2/show/NCT01841762?term=macitentan&rank=5. Accessed October 27, 2013.
33. ClinicalTrials.gov. AC-055-402: an extension of AC-055-401, study of macitentan in patients with PAH to psychometrically validate PAH-SYMPACT instrument (SYMPHONYext). http://www.clinicaltrials.gov/ct2/show/NCT01847014?term=macitentan&rank=8. Accessed October 27, 2013.
34. ClinicalTrials.gov. MAESTRO (Macitentan in eisenmenger syndrome to restore exercise capacity). http://www.clinicaltrials.gov/ct2/show/NCT01743001?term=macitentan&rank=7. Accessed October 27, 2013.
35. Corallo C,Pecetti G,Iglarz M, et al.Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings.J Biol Regul Homeost Agents. 2013;27:455-462.
36. Sen S,Chen S,Feng B,Iglarz M,Chakrabarti S.Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist.Life Sci. 2012;91:658-668.
37. Coffman L,Mooney C,Lim J, et al.Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells.Cancer Biol Ther. 2013;14:184-192.
38. Kim SJ,Kim JS,Kim SW, et al.Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.Neoplasia. 2011;13:167-179.
39. Kim SJ,Kim JS,Kim SW, et al.Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.Transl Oncol. 2012;5:39-47.
40. ClinicalTrials.gov. Macitentan for the treatment of digital ulcers in systemic sclerosis patients (DUAL-1). http://www.clinicaltrials.gov/ct2/show/NCT01474109?term=macitentan&rank=1. Accessed October 27, 2013.
41. ClinicalTrials.gov. Macitentan in combo with dose-dense temozolomide in patients with recurrent glioblastoma. http://www.clinicaltrials.gov/ct2/show/NCT01499251?term=macitentan&rank=4. Accessed October 27, 2013.
42. Bruderer S,Aanismaa P,Homery MC, et al.Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.AAPS J. 2012;14:68-78.
43. Weiss J,Theile D,Ruppell MA,Speck T,Spalwisz A,Haefeli WE.Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro.Eur J Pharmacol. 2013;701:168-175.
44. Atsmon J,Dingemanse J,Shaikevich D,Volokhov I,Sidharta PN.Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.Clin Pharmacokinet. 2013;52:685-692.
45. Foster City, CA: Gilead Sciences, Inc; 2013:.
46. South San Francisco, CA: Actelion Pharmaceuticals US, Inc; 2012:.
47. US Food and Drug Administration (FDA). Orange Book: approved drug products with therapeutic equivalence equations. http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed October 27, 2013.
48. Ambrisentan. Red Book Online®. Truven Health Analytics. Accessed October 27, 2013. http://www.micromedexsolutions.com/micromedex2/librarian/.
49. Bosentan. Red Book Online®. Truven Health Analytics. Accessed October 27, 2013. http://www.micromedexsolutions.com/micromedex2/librarian/.
50. Macitentan. Red Book Online®. Truven Health Analytics. Accessed October 27, 2013. http://www.micromedexsolutions.com/micromedex2/librarian/.
51. Kirson NY,Birnbaum HG,Ivanova JI,Waldman T,Joish V,Williamson T.Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.Appl Health Econ Health Policy. 2011;9:377-387.
52. Strange G,Keogh A,Dalton B,Gabbay E.Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension.Expert Rev Pharmacoecon Outcomes Res. 2011;11:253-263.
53. PhRMA.org. Medicines in development: rare diseases. http://phrma.org/sites/default/files/pdf/Rare_Diseases_2013.pdf. Accessed October 27, 2013.